FRIDAY, DECEMBER 9, 2011 (PUBLISHED ON WWW.CELLTHERAPYBLOG.COM)
Active phase III or II/III cell therapy trials
I know that the moment I publish anything that purports to be comprehensive there will be
errors and omissions. At the very least it will almost imminently be out-of-date in a fast-
moving sector like cell therapy.
Nonetheless, because there is no other reliable repository of this information, I am daring to
put this out there and hope you will feel obligated to assist me in ensuring its accuracy
rather than critical of the effort.
What follows is what I currently believe to an current and relatively comprehensive list of
phase III or II/III cell therapy trials around the world. I am more confident of the industry
list than the academic one. More confident of its completeness and accuracy for North
American and Europe than of Asia (particularly China).
There is a spreadsheet behind this that includes more data fields like therapeutic category,
cell/tissue source, cell type, expansion, indication, expected completion date, clinical trial
site locations, etc. If you want a copy of it, just email me (I'm not hard to find) or comment
below.
INDUSTRY PHASE III or II/III (active or expected to be active in 1H 2012)
Aastrom Ixmyelocel-T
Baxter ACT34-CMI
Bioheart Myocell
Cardio3 Biosciences C-CURE
Cardio3 Biosciences C-CURE
Cell Medica adoptive cellular therapy
Cook Myosite AMDC
Cytori ADRCs
GamidaCell - Teva StemEx
Genzyme MACI
Harvest Technologies SmartPReP 2 BMAC
Innovaell IES13 (Urocell?)
Kiaidis Pharma ATIR
Miltenyi CliniMACS CD34 Selection System
Medipost Cartistem
MolMed TK
Newlink Genetics HyperAcute Pancreas
NovaRx Lucanix
Osiris Prochymal
Osiris Prochymal
Pervasis Vasugel
www.celltherapygroup.com www.celltherapyblog.com
The 21 active or imminently active cell therapy industry-sponsored trials listed above break
down as follows:
o 52% (12) are autologous
o 33% (7) are allogeneic
o Two are gene-modified allogeneic
o One involves autologous and allogeneic cells
o 24% (5) are for cardiac-related indications
o 33% (7) are for oncology or related indications
o Two are for cartilage repair
* ACADEMIC PHASE III or II/III
Assistance Publique - Hôpitaux de Paris (France)
Association of Dutch Burn Centres (Netherlands)
Barts and The London NHS Trust (UK)
Erasmus Medical Center (Netherlands)
European Group for Blood and Marrow Transplantation (Europe)
Leiden University Medical Center (Netherlands)
Meshalkin Research Institute of Pathology of Circulation (Russia)
Meshalkin Research Institute of Pathology of Circulation (Russia)
Ministry of Health (Malaysia)
Royan Institute (Iran)
Rush University Medical Center, University of Sao Paulo, Uppsala University (US,
Brazil, Sweden)
Third Military Medical University (Chia)
University of Minnesota, Masonic Cancer Center (US)
University of Minnesota, Masonic Cancer Center (US)
University Hospital of North Norway (Norway)
University of Utah (US)
* Active trials only - excludes trials which appear inactive, abandoned, and/or are stem cell
transplant in oncology. Primary source is CinicalTrials.gov.
___________________________________
I will try to keep this list updated at least once-per-quarter and indicate the date of the last
update at the top of the post.
I eagerly encourage all readers to comment below or email direct with any errors and/or
omissions.
www.celltherapygroup.com www.celltherapyblog.com